Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

LKAB’s interim report for the third quarter 2023 to be published on 27 October

LKAB’s interim report for the third quarter 2023 will be published on LKAB’s website at around 15.00 CEST on 27 October.The report will be sent out as a press release and published at https://lkab.com/en/financial-information/.  LKAB’s President and CEO Jan Moström will be available for comments by phone. Calls may be booked through Niklas Johansson, Senior Vice President Communication and Climate, on +46 10 144 52 19 or Frida Dagertun, Investor Relations, on +46 920 380 70.

SmartCraft ASA (SMCRT) - Invitation to presentation of third quarter 2023 results

25 October 2023 - SmartCraft ASA will publish its third quarter 2023 financial report on Wednesday 1 November 2023 at 07:00 CET together with the Q3 2023 presentation material on the company website and www.newsweb.no. Investors, analysts, and journalists are welcome to join to an English language webcast presentation of the report on the same day, Wednesday 1 November 2023, at 08:00 CET. Webcast link: https://channel.royalcast.com/landingpage/hegnarmedia/20231101_5/ Presenters: · Chief Executive Officer Gustav Line · Chief Financial Officer Kjartan Bø Viewers are

UNION therapeutics to present at 7th Annual Dermatology Drug Development Summit in Boston

Hellerup, Denmark, October 25, 2023 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. Kjøller, CEO of UNION therapeutics will present at the seminar on clinical trials at the 7th Annual Dermatology Drug Development Summit on October 31 - November 2, 2023, in Boston, US. Dr. Kjøller will discuss recent challenges and progress in assessing efficacy in clinical trials of hidradenitis suppurativa (HS) and how novel endpoints may improve the approach. To

Avensia Helps Businesses Make Smarter Decisions in Ever-Changing Market Conditions

Modern commerce expert Avensia announces a new partnership with global digital experience analytics provider Contentsquare. Working with Contentsquare, Avensia will be able to help commerce businesses transform into agile and data-driven organizations in order to quickly respond to the ever-changing market conditions. The two companies are already working together with shared retail customers.In today’s challenging commerce landscape understanding the customer – their needs, preferences and behaviors – is crucial. This detailed understanding is the key to providing relevant, personalized

First patient treated in the second dose group in Annexin's RVO study

Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company's clinical phase 2 study in patients with retinal vein occlusion (RVO) with the investigational drug candidate ANXV. No limiting treatment-related side effects have been reported and the company has received recommendation to proceed with treatment of patients in the next dose group. An expected accelerated recruitment rate means that last patient in is planned to the first quarter of 2024.“It is very gratifying that we see continued progress in this

Wyld Networks, Vracity and Brinja sign an agreement to develop infrastructure asset monitoring in the Kingdom of Saudi Arabia

The synergy of Wyld Network’s cutting-edge satellite IoT connectivity, Vracity’s advanced digital twin technology, and Brinja’s state-of-the-art construction monitoring and application technology is set to usher in a transformative era in infrastructure and utilities maintenance monitoring across the entirety of Saudi Arabia.This comprehensive integration will empower us to detect and analyse various aspects of infrastructure, including structural integrity, weathering, cracks, vibrations, and anomalies. These insights will play a pivotal role in informing ongoing planning and maintenance

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks.    The data update will be part of Medivir’

Sleep Cycle interim report July-September 2023:  Increased operating margin and trend shift in subscription development

Göteborg, Sweden, 25 October 2023.The third quarter in summary (July-September 2023) · Net sales increased by 11.1% (12.8%) and totaled tSEK 61,065 (54,976). Currency-adjusted net sales growth totaled 2.6% (7.3%). · Operating profit totaled tSEK 20,427 (13,563) and the operating margin was 33.5% (24.7%). No expenses affecting comparability have been expensed. · The total number of paying subscribers at the end of the period was 887,000 (912,000), a decrease of 2.7% compared with the previous year. · Average Revenue per User (ARPU) for the quarter totaled SEK 276 (239), a

Strong profit growth, including a sequential volume improvement

AAK Group · Total volumes decreased by 5 percent to 529,000 MT (559,000), mainly due to declines in Chocolate & Confectionery Fats and the optimization program in Bakery.  · Including currency translation gains of SEK 32 million, operating profit increased by 39 percent, reaching SEK 1,143 million (822). At fixed foreign exchange rates, operating profit, increased by 35 percent.  · Profit for the period totalled SEK 807 million (611). · Earnings per share equalled SEK 3.10 (2.36).  · Cash flow from operating activities amounted to SEK 1,214 million (negative 40).  ·

Prominent Italian ALS expert Adriano Chiò joins TikoMed’s Scientific Advisory Board (SAB)

Viken, Sweden – October 25, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Adriano Chiò, of the University of Torino and the Città della Salute e della Scienza Hospital as the fourth member of its newly formed Scientific Advisory Board.Adriano Chiò is a neurologist currently working in Torino, Italy. He is Professor of Neurology and Director of the 1st Neurology Unit at the University of Torino and the Città della Salute e della Scienza Hospital, Torino, Italy. Professor Chiò is also a member of the board and Treasurer of the European

Greenfood Greenhouse crowned Logistics Facility of the Year 2023

This year, 40 new logistics facilities competed for the title of "2023 Logistics Facility of the Year." They were evaluated on criteria like innovation, environmental commitment, operational efficiency, and employee well-being. The results are in, and Greenfood's state-of-the-art Greenhouse facility in Helsingborg is the winner.Annually, the business magazine Intelligent Logistics presents this prestigious award. Out of an initial 40, only five were shortlisted as finalists. Today, it's been announced that Greenfood's Greenhouse has clinched the top spot. Greenhouse was developed to

BioStock: Oncoinvent’s CEO comments on Q3 and funding plans

The third quarter was a productive period for Oncoinvent, marked by significant milestones in the clinical development of the radiopharmaceutical Radspherin. Among other things, the company showcased clinical data for the candidate at two large congresses. To gear up for phase IIb in 2024, the company is now planning to raise capital. BioStock reached out to CEO Anders Månsson to find out more.Read the full interview with Anders Månsson at biostock.se: https://www.biostock.se/en/2023/10/oncoinvents-ceo-comments-on-q3-and-funding-plans/ This is a press release from BioStock -

Q3/2023: LeadDesk grew and improved its EBITDA

LeadDesk Plc unofficial translation of Company Release 25/10/2023 at 9.20 amFigures in parentheses refer to the equivalent period in the previous year unless otherwise stated. Figures presented in this business review are unaudited.  July–September 2023 · Revenue EUR 7,336 (7,012) thousand, growth 4.6% · Annual recurring revenue contract base EUR 25,709 (23,825) thousand, growth 7.9%[1] · EBITDA EUR 1,095 (996) thousand, 14.9% (14.2) of revenue January–September 2023 · Revenue EUR 21,809 (20,776) thousand, growth 5.1% · Annual recurring revenue contract base EUR

Bio-Works secures 0.8 MSEK order for gene therapy manufacturing

Bio-Works has confirmed a new order for a customized, prepacked solution worth 0.8 MSEK to be used in a viral vector manufacturing process. The initial order is for process validation runs, and the potential annual revenue from the project is estimated to be between 3-12 MSEK.The customer is an American contract manufacturer of gene therapy products. “I am happy to see that our focus on customized solutions is paying off,” said Jonathan Royce, CEO at Bio-Works. “Bio-Works is providing solutions to biotech companies that other suppliers cannot offer, and we are making good progress to

Donkey Republic reports best performing quarter in the history of the company by realizing strong results of 11M DKK EBITDA and 40.9M DKK revenue in Q3-2023

Company Announcement no. 24-2023KPI report Q3-2023 Positive EBITDA of 11M DKK in Q3-2023 supports the trend from H1-2023 and puts the company in a strong position to deliver on the strategy for 2023Achieving 11M DKK EBITDA in Q3-2023 confirms the trend and momentum reported in H1-2023 to deliver profitable growth. As reported in company announcement no.23-2023, the company raised the upper levels for EBITDA guidance for 2023 to 9-13.5M DKK. The EBITDA performance for Q3-2023 can be attributed to the following items: • Higher than expected performance on rider revenue over the

AcadeMedia’s interim report, July 2023 – September 2023

First quarter (July – September 2023) · Net sales increased by 10.5 percent and amounted to SEK 3,430 million (3,104). Organic growth, including bolt-on acquisitions, was 6.5 percent. · Operating profit (EBIT) amounted to SEK 232 million (239). · Adjusted operating profit, adjusted for items affecting comparability and effects of IFRS 16, amounted to SEK 151 million (151). Items affecting comparability amounted to SEK -6 million (6). · Net profit for the period amounted to SEK 62 million (94). · Earnings per share was SEK 0.59 (0.73) after dilution. Adjusted for IFRS 16,

Kamux Corporation’s financial reporting and AGM in 2024

Kamux Corporation, Stock Exchange Release, 25.10.2023 at 9:00 Kamux Corporation’s financial reporting and AGM in 2024 Publication schedule for Kamux Corporation’s financial reporting in 2024 is as follows: Financial Statements Bulletin 2023                     March 1, 2024 Interim Report for January—March 2024            May 17, 2024 Half-Year Report for January—June 2024          August 16, 2024 Interim Report for January—September 2024   November 8, 2024 The Annual Report for 2023 including Financial Statements will be published on the week commencing March 25, 2024.

COP28: Finnish business calls for climate action and offers practical solutions at UN Climate Change Conference

Finland will call for ‘action over words’ at the 2023 United Nations Climate Change Conference, highlighting the importance of taking real climate action. This year, for the first time, Finland and Finnish partner companies will be showcasing key solutions to accelerate the fight against climate change at the Finland Pavilion. This expanded presence underlines Finland’s climate commitment, which includes the country’s ambitious climate targets: 2035 carbon neutrality targets, doubling emission-free electricity production and capturing industrial carbon dioxide emissions by mid-2030’s.

JM Interim Report January–September 2023

Focus on cash flow in a challenging housing market• Revenue amounted to SEK 10,444m (11,233). • Operating profit decreased to SEK 822m (1,297). The operating margin decreased to 7.9 percent (11.6). • Profit before tax decreased to SEK 746m (1,249), and profit after tax decreased to SEK 570m (982). • Return on equity for the past twelve months amounted to 13.5 percent (19.9). • Earnings per share amounted to SEK 8.90 (14.50). • Consolidated cash flow including net investment in properties amounted to SEK −452m (−615). • The number of residential units sold decreased to 1,

Quarterly Report Q3 2023

Continued strong executionThird quarter ·Net sales increased by 16% to SEK 36,881 M (31,820), with organic growth of 1% (14) and acquired net growth of 11% (3). Exchange-rates affected sales by 4% (16). ·Good organic sales growth in Global Technologies and Americas, stable organic sales in Entrance Systems, while organic sales declined in Asia Pacific and EMEIA. ·Ten acquisitions with combined annual sales of about SEK 2,000 M were signed in the quarter. ·The operating margin (EBITA) was 16.7% (16.2). ·Operating income[1] (EBIT) increased by 16% and

Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children

· The European Paediatric Committee (PDCO) has agreed to a 50% reduction in the number of children required in the final safety study (0202) of CT001 for the treatment of acute and procedural pain in children · New safety data from both adult and paediatric studies has been presented to PDCO and based on this information, the PDCO agreed to the proposed reduction in number of children · With this PDCO opinion, study 0202 will have a much shorter recruitment period and at less costs that previously anticipated. The study is now approved by the competent authorities in Spain and UKOn 25

Invitation to Eltel’s Q3 2023 report presentation

Eltel will publish its report for the period January-September 2023 on Thursday 2 November 2023 at approximately 08.00 am CET. On the same day, we are inviting investors, analysts and media to a combined webcast and teleconference starting at 10:00 am CET.The report for the period January-September 2023 will be presented by Eltel’s President and CEO Håkan Dahlström and CFO Tarja Leikas. The presentation will be held in English. Link to webcast: www.eltelgroup.com. You can access the teleconference by registering on the link below. After registration, you will be provided phone numbers

Interim Report Byggmax Group 1 January - 30 September, 2023

Profitable Byggmax in weak marketSummary of the third quarter of 2023• Net sales amounted to SEK 1,960 M (2,273), representing a decrease of 13.8 percent.• The Group’s currency adjusted like-for-like sales decreased by 15.5 percent.• The gross margin was 34.1 percent (34.4).• EBITA amounted to SEK 210 M (288), with an EBITA margin of 10.7 percent (12.7).• EBIT amounted to SEK 196 M (274), with an EBIT margin of 10.0 percent (12.0).• Net profit for the period amounted to SEK 138 M (214).• Earnings per share totalled SEK 2.36 (3.65).• Cash flow from operating activities

There are no items matching the current filter
There are no more items matching the current filter
Back to top